Usefulness of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Takahiro YokoseMinoru KitagoYohji MatsusakaYohei MasugiMasahiro ShinodaHiroshi YagiYuta AbeGo OshimaShutaro HoriYutaka EndoKenji ToyamaYu IwabuchiRyo TakemuraRyota IshiiTadaki NakaharaShigeo OkudaMasahiro JinzakiYuko KitagawaPublished in: Cancer medicine (2020)
PERCIST was more accurate in determining NAT's therapeutic effects for PDAC than RECIST. MTV reduction rates were independent prognostic factors for PDAC.